Study on the mechanism of Shanxi genuine drug food homologous substances in preventing type 2 diabetes complicated with hypertension based on reverse network pharmacology_West China Medical Journal

Authors：

ZENG Jinghui ¹ , SONG Kai ¹ , LI Na ¹ , ZHANG Jing ¹ , YANG Longhui ¹ ,  ZHU Ruifang ^1,2

1. School of Nursing, School of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi 030001, P. R. China;
2. Editorial Department, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P. R. China;

Corresponding?author：

ZHU Ruifang, Email: ruifang.zhu@sxmu.edu.cn

Keywords：

Type 2 diabetes; hypertension; drug food homologous; reverse network pharmacology

DOI：

10.7507/1002-0179.202503136

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To find out Shanxi genuine drug food homologous substances for type 2 diabetes complicated with hypertension, and to explore its mechanism. Methods The targets of type 2 diabetes and hypertension were obtained from TTD, Drugbank and GeneCards databases, and the intersection targets of the two were obtained. After UniProt database transformation, the protein-protein interaction network was established on the String platform. Degree values were used to screen core targets, followed by enrichment analysis. TCMSP database was used to carry out reverse screening of traditional Chinese medicine ingredients and corresponding traditional Chinese medicine. The key target-active ingredient-traditional Chinese medicine network was constructed. Chinese medicine with a certainty value≥3 was overlapped with drug food homology directory, Shanxi genuine drug directory, and drug use law directory of type 2 diabetes complicated with hypertension to obtain the best drug food homologous substances. Results After screening, 715 intersecting targets were identified, 23 key targets and 818 traditional Chinese medicine ingredients were determined, and 24 active ingredients with retention values≥4 were identified as core active ingredients. A total of 302 traditional Chinese medicines were reverse screened. There were 14 kinds of drug food homologous substances, and Radix Astragali was finally selected as the best drug food homologous substance for type 2 diabetes complicated with hypertension. Conclusion Radix Astragali may be used to prevent and treat type 2 diabetes complicated with hypertension, but the related research only involves theoretical aspects, which needs to be verified by trials in the future.

Citation： ZENG Jinghui, SONG Kai, LI Na, ZHANG Jing, YANG Longhui, ZHU Ruifang. Study on the mechanism of Shanxi genuine drug food homologous substances in preventing type 2 diabetes complicated with hypertension based on reverse network pharmacology. West China Medical Journal, 2026, 41(1): 65-71. doi: 10.7507/1002-0179.202503136 Copy

1.	Bakris G. Similarities and differences between the ACC/AHA and ESH/ESC guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults. Circ Res, 2019, 124(7): 969-971.
2.	張潔, 何青芳, 王立新, 等. 浙江省成人高血壓合并糖尿病患病率及心血管病風險分析. 預防醫學, 2018, 30(2): 109-112.
3.	中國醫師協會中西醫結合醫師分會內分泌與代謝病學專業委員會, 倪青. 糖尿病高血壓病證結合診療指南. 環球中醫藥, 2024, 17(1): 173-187.
4.	陳小露, 張耀東, 王立軍, 等. 網絡藥理學在中藥治療糖尿病領域的研究進展. 中藥材, 2021, 44(9): 2245-2250.
5.	孫欣緣, 鄭雅萍, 孫康萌, 等. 我國食藥物質名單梳理、修訂與展望. 中國中藥雜志, 2025, 50(2): 346-355.
6.	劉曉倩. 基于數據挖掘和網絡藥理學的中藥復方治療 2 型糖尿病合并高血壓用藥規律及機制分析. 沈陽: 遼寧中醫藥大學, 2022.
7.	金恒伊. 基于數據挖掘探討 2 型糖尿病合并高血壓證型特點和用藥規律. 沈陽: 遼寧中醫藥大學, 2024.
8.	李佳蓓, 劉春華, 李潔花, 等. 中醫藥治療 2 型糖尿病合并原發性高血壓氣陰兩虛證用藥規律探析. 湖南中醫雜志, 2023, 39(5): 21-26.
9.	高昆, 林洪源. 山西省道地中藥材研究進展. 山西農業科學, 2023, 51(12): 1457-1467.
10.	Martín-Vázquez E, Cobo-Vuilleumier N, López-Noriega L, et al. The PTGS2/COX2-PGE2 signaling cascade in inflammation: pro or anti? A case study with type 1 diabetes mellitus. Int J Biol Sci, 2023, 19(13): 4157-4165.
11.	Guzik TJ, Nosalski R, Maffia P, et al. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol, 2024, 21(6): 396-416.
12.	Barreto-Andrade JN, de Fátima LA, Campello RS, et al. Estrogen receptor 1 (ESR1) enhances Slc2a4/GLUT4 expression by a SP1 cooperative mechanism. Int J Med Sci, 2018, 15(12): 1320-1328.
13.	江順利. 雙酚 A 及其替代物暴露與高血壓的關聯研究. 武漢: 華中科技大學, 2020.
14.	林智立, 雷蕾, 李長潤, 等. 胰島炎癥導致的 2 型糖尿病發病過程的動力學模型及治療策略. 北京大學學報(自然科學版), 2021, 57(2): 199-208.
15.	Plante TB, Juraschek SP, Howard G, et al. Cytokines, C-reactive protein, and risk of incident hypertension in the REGARDS study. Hypertension, 2024, 81(6): 1244-1253.
16.	Kay AM, Simpson CL, Stewart JA Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diabetes Res, 2016, 2016: 6809703.
17.	Li WH, Chang ST, Chang SC, et al. Isolation of antibacterial diterpenoids from cryptomeria japonica bark. Nat Prod Res, 2008, 22(12): 1085-1093.
18.	郭勝男, 張莉, 吳深濤, 等. 典型黃酮類化合物改善胰島素抵抗研究進展. 西部中醫藥, 2022, 35(11): 144-148.
19.	Muruganathan N, Dhanapal AR, Baskar V, et al. Recent updates on source, biosynthesis, and therapeutic potential of natural flavonoid luteolin: a review. Metabolites, 2022, 12(11): 1145.
20.	楊耀, 陳波, 梁凱倫, 等. 蒙花苷與木犀草素聯用對離體血管的舒張作用及其機制研究. 中國中藥雜志, 2017, 42(7): 1370-1375.
21.	Qu JT, Zhang DX, Liu F, et al. Vasodilatory effect of wogonin on the rat aorta and its mechanism study. Biol Pharm Bull, 2015, 38(12): 1873-1878.
22.	Lei L, Zhao J, Liu XQ, et al. Wogonin alleviates kidney tubular epithelial injury in diabetic nephropathy by inhibiting PI3K/Akt/NF-κB signaling pathways. Drug Des Devel Ther, 2021, 15: 3131-3150.
23.	Chiefari E, Mirabelli M, La Vignera S, et al. Insulin resistance and cancer: in search for a causal link. Int J Mol Sci, 2021, 22(20): 11137.
24.	朱海瑀, 管洪藝, 閆慧新, 等. 中醫藥通過調控 PI3K/Akt 信號通路防治 2 型糖尿病肝臟胰島素抵抗的研究進展. 吉林中醫藥, 2023, 43(11): 1356-1360.
25.	Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci, 2018, 14(11): 1483-1496.
26.	Khalid M, Alkaabi J, Khan MAB, et al. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci, 2021, 22(16): 8590.
27.	黃峰. AGEs-RAGE 在自發性高血壓大鼠腦組織的表達及藥物干預的研究. 福州: 福建醫科大學, 2010.
28.	李琳, 劉瑜, 劉屏, 等. 黃芪多糖對 MIN6 細胞增殖、凋亡及胰島素分泌的影響. 中國新藥雜志, 2011, 20(21): 2139-2142.
29.	陳思羽, 唐思夢, 王穎, 等. 黃芪多糖對 2 型糖尿病模型大鼠餐后 1 h 血糖的影響. 中藥新藥與臨床藥理, 2020, 31(4): 396-401.
30.	季天嬌. 黃芪甲苷調節 PI3K/Akt 通路來改善 2 型糖尿病大鼠肝糖代謝異常的分子機制. 合肥: 安徽醫科大學, 2020.
31.	劉曉睿, 李健. 黃芪有效成分的降壓、降脂作用. 中國老年學雜志, 2015, 35(17): 4800-4801.
32.	鞏莎, 可海霞. 黃芪甲苷通過抑制氯化物細胞內通道蛋白 4/ADP 核糖基化因子 6 信號通路改善血管緊張素Ⅱ誘導的高血壓大鼠模型的心肌損傷. 中華高血壓雜志, 2024, 32(1): 43-50.

1. Bakris G. Similarities and differences between the ACC/AHA and ESH/ESC guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults. Circ Res, 2019, 124(7): 969-971.
2. 張潔, 何青芳, 王立新, 等. 浙江省成人高血壓合并糖尿病患病率及心血管病風險分析. 預防醫學, 2018, 30(2): 109-112.
3. 中國醫師協會中西醫結合醫師分會內分泌與代謝病學專業委員會, 倪青. 糖尿病高血壓病證結合診療指南. 環球中醫藥, 2024, 17(1): 173-187.
4. 陳小露, 張耀東, 王立軍, 等. 網絡藥理學在中藥治療糖尿病領域的研究進展. 中藥材, 2021, 44(9): 2245-2250.
5. 孫欣緣, 鄭雅萍, 孫康萌, 等. 我國食藥物質名單梳理、修訂與展望. 中國中藥雜志, 2025, 50(2): 346-355.
6. 劉曉倩. 基于數據挖掘和網絡藥理學的中藥復方治療 2 型糖尿病合并高血壓用藥規律及機制分析. 沈陽: 遼寧中醫藥大學, 2022.
7. 金恒伊. 基于數據挖掘探討 2 型糖尿病合并高血壓證型特點和用藥規律. 沈陽: 遼寧中醫藥大學, 2024.
8. 李佳蓓, 劉春華, 李潔花, 等. 中醫藥治療 2 型糖尿病合并原發性高血壓氣陰兩虛證用藥規律探析. 湖南中醫雜志, 2023, 39(5): 21-26.
9. 高昆, 林洪源. 山西省道地中藥材研究進展. 山西農業科學, 2023, 51(12): 1457-1467.
10. Martín-Vázquez E, Cobo-Vuilleumier N, López-Noriega L, et al. The PTGS2/COX2-PGE2 signaling cascade in inflammation: pro or anti? A case study with type 1 diabetes mellitus. Int J Biol Sci, 2023, 19(13): 4157-4165.
11. Guzik TJ, Nosalski R, Maffia P, et al. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol, 2024, 21(6): 396-416.
12. Barreto-Andrade JN, de Fátima LA, Campello RS, et al. Estrogen receptor 1 (ESR1) enhances Slc2a4/GLUT4 expression by a SP1 cooperative mechanism. Int J Med Sci, 2018, 15(12): 1320-1328.
13. 江順利. 雙酚 A 及其替代物暴露與高血壓的關聯研究. 武漢: 華中科技大學, 2020.
14. 林智立, 雷蕾, 李長潤, 等. 胰島炎癥導致的 2 型糖尿病發病過程的動力學模型及治療策略. 北京大學學報(自然科學版), 2021, 57(2): 199-208.
15. Plante TB, Juraschek SP, Howard G, et al. Cytokines, C-reactive protein, and risk of incident hypertension in the REGARDS study. Hypertension, 2024, 81(6): 1244-1253.
16. Kay AM, Simpson CL, Stewart JA Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diabetes Res, 2016, 2016: 6809703.
17. Li WH, Chang ST, Chang SC, et al. Isolation of antibacterial diterpenoids from cryptomeria japonica bark. Nat Prod Res, 2008, 22(12): 1085-1093.
18. 郭勝男, 張莉, 吳深濤, 等. 典型黃酮類化合物改善胰島素抵抗研究進展. 西部中醫藥, 2022, 35(11): 144-148.
19. Muruganathan N, Dhanapal AR, Baskar V, et al. Recent updates on source, biosynthesis, and therapeutic potential of natural flavonoid luteolin: a review. Metabolites, 2022, 12(11): 1145.
20. 楊耀, 陳波, 梁凱倫, 等. 蒙花苷與木犀草素聯用對離體血管的舒張作用及其機制研究. 中國中藥雜志, 2017, 42(7): 1370-1375.
21. Qu JT, Zhang DX, Liu F, et al. Vasodilatory effect of wogonin on the rat aorta and its mechanism study. Biol Pharm Bull, 2015, 38(12): 1873-1878.
22. Lei L, Zhao J, Liu XQ, et al. Wogonin alleviates kidney tubular epithelial injury in diabetic nephropathy by inhibiting PI3K/Akt/NF-κB signaling pathways. Drug Des Devel Ther, 2021, 15: 3131-3150.
23. Chiefari E, Mirabelli M, La Vignera S, et al. Insulin resistance and cancer: in search for a causal link. Int J Mol Sci, 2021, 22(20): 11137.
24. 朱海瑀, 管洪藝, 閆慧新, 等. 中醫藥通過調控 PI3K/Akt 信號通路防治 2 型糖尿病肝臟胰島素抵抗的研究進展. 吉林中醫藥, 2023, 43(11): 1356-1360.
25. Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci, 2018, 14(11): 1483-1496.
26. Khalid M, Alkaabi J, Khan MAB, et al. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci, 2021, 22(16): 8590.
27. 黃峰. AGEs-RAGE 在自發性高血壓大鼠腦組織的表達及藥物干預的研究. 福州: 福建醫科大學, 2010.
28. 李琳, 劉瑜, 劉屏, 等. 黃芪多糖對 MIN6 細胞增殖、凋亡及胰島素分泌的影響. 中國新藥雜志, 2011, 20(21): 2139-2142.
29. 陳思羽, 唐思夢, 王穎, 等. 黃芪多糖對 2 型糖尿病模型大鼠餐后 1 h 血糖的影響. 中藥新藥與臨床藥理, 2020, 31(4): 396-401.
30. 季天嬌. 黃芪甲苷調節 PI3K/Akt 通路來改善 2 型糖尿病大鼠肝糖代謝異常的分子機制. 合肥: 安徽醫科大學, 2020.
31. 劉曉睿, 李健. 黃芪有效成分的降壓、降脂作用. 中國老年學雜志, 2015, 35(17): 4800-4801.
32. 鞏莎, 可海霞. 黃芪甲苷通過抑制氯化物細胞內通道蛋白 4/ADP 核糖基化因子 6 信號通路改善血管緊張素Ⅱ誘導的高血壓大鼠模型的心肌損傷. 中華高血壓雜志, 2024, 32(1): 43-50.

West China Medical Journal

Study on the mechanism of Shanxi genuine drug food homologous substances in preventing type 2 diabetes complicated with hypertension based on reverse network pharmacology

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content